what's the buzz

 As part of the research, Terry Nolan, from the University of Melbourne, Australia, and colleagues examined the effectiveness of two doses of a 2009 influenza A(H1N1) vaccine in 370 healthy infants and children.
The kids were aged between 6 months to less than 9 years and. They were divided into groups before they received a two-injection regimen in a gap of 21 days. The vaccine dose was limited to either 15-micrograms or 30-micrograms. The experts noted that every child had achieved an antibody level considered high enough to protect against the virus.

Heart transplant patients at  risk of multiple skin cancers
Many heart transplant patients have elevated risk for developing multiple skin cancers, according to a new study.
 Jerry D Brewer, of Mayo Clinic, Rochester, Minn., and colleagues reviewed the records of 312 patients who had received heart transplants between 1988 and 2006.
 Patients had an average age of 47.4 years at the time of their transplant and information was extracted from their charts regarding overall characteristics, cancers, risk factors and death.
 The patients developed a total of 1,395 skin cancers; overall, 46.4 percent of the patients had developed skin cancer during the 19 years of follow-up.
 When evaluating the tumor burden of the 312 patients, 76 (24.4 percent) had at least one squamous cell carcinoma, 24 (7.7 percent) had only one squamous cell carcinoma and 19 (6.1 percent) had 10 or more; in addition, 54 (17.3 percent) had at least one basal cell carcinoma, 23 (7.4 percent) had only one and two (0.6 percent) had 10 or more.

Banned ingredient linked to urinary tract cancer risk
The consumption of popular Chinese herbal products containing carcinogen aristolochic acid is linked to an increased risk of urinary tract cancer, a new study has foundMany countries, such as Taiwan, have banned products containing aristolochic acid because of clinical cases of urothelial cancer in association with aristolochic acid use. To examine this association, Jung-Der Wang, , of the Institute of Occupational Medicine and Industrial Hygiene, College of Public Health, at the National Taiwan University, and colleagues conducted a population-based case-control study of Taiwanese patients newly diagnosed with urinary tract cancer .
 
Gene therapy to prevent lung disease progression
Boston University researchers have found a new gene therapy to thwart the progression of emphysema, a lung disease.
 Alpha-1 Anti-trypsin Deficiency is the most frequently inherited form of emphysema found in young people due to a mutation in the Alpha-1 Anti-trypsin gene. This genetic disorder makes individuals susceptible to early emphysema and liver cirrhosis.
The team from Boston University School of Medicine (BUSM) experimented on mice and found a way to transport genes selectively to nearly 70 percent of a mouse lung's alveolar macrophages (AM), an important cell contributing to emphysema. Andrew Wilson, lead author of the study and an assistant professor of medicine at BUSM, said: “The progression of emphysema in mice exposed to elastase was significantly improved by the gene therapy as evidenced by improvements.”

Liked the story?

  • 0

    Happy
  • 0

    Amused
  • 0

    Sad
  • 0

    Frustrated
  • 0

    Angry